|1.||Saif, Muhammad Wasif: 35 articles (12/2015 - 07/2005)|
|2.||Cunningham, D: 28 articles (03/2015 - 01/2001)|
|3.||Kim, Tae Won: 27 articles (09/2014 - 07/2003)|
|4.||Park, Young Suk: 23 articles (10/2015 - 01/2004)|
|5.||Kang, Yoon-Koo: 23 articles (03/2015 - 07/2003)|
|6.||Cunningham, David: 22 articles (07/2015 - 07/2005)|
|7.||Cassidy, J: 20 articles (06/2012 - 01/2000)|
|8.||Lee, Jeeyun: 18 articles (10/2015 - 07/2005)|
|9.||Twelves, C: 17 articles (05/2012 - 03/2000)|
|10.||Twelves, Chris: 16 articles (12/2015 - 01/2002)|
|1.||Breast Neoplasms (Breast Cancer)
08/01/2007 - "The oral fluoropyrimidine carbamate, capecitabine, is a highly active and well-tolerated treatment for metastatic breast cancer. "
01/01/2001 - "Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings."
01/01/2012 - "Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer."
01/01/2012 - "We found significant improvement in the additional capecitabine arm versus control in disease-free survival (DFS) (HR = 0.83, 95% CI: 0.71-0.98, P = 0.027), overall survival (OS) (HR = 0.71, 95% CI: 0.57-0.88, P = 0.002), distant recurrence (HR = 0.79, 95% CI: 0.66-0.94, P = 0.008) and the death from breast cancer only (HR = 0.65, 95% CI: 0.51-0.83, P = 0.001). "
01/01/2010 - "Oral capecitabine (CAP) has shown significant benefits in early stage breast cancer (BC). "
|2.||Colorectal Neoplasms (Colorectal Cancer)
04/01/2010 - "To date, the economic evaluation literature has consistently projected or found that capecitabine is not only a cost-effective treatment for adjuvant or for metastatic colorectal cancer (i.e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings."
01/01/2007 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). "
06/01/2004 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). "
07/01/2006 - "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV. "
12/01/2003 - "Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. "
11/01/2003 - "Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. "
01/01/2009 - "In the HT29 model, tumor growth inhibition and increase in life span (ILS) were significantly greater with capecitabine 7/7 than with 14/7 (P<0.05). "
01/01/2010 - "Subsequent preclinical studies demonstrated that this biweekly capecitabine schedule allowed for safe delivery of higher daily doses, improved tumor response, and prolonged animal survival. "
01/01/2004 - "Expression of TP in tumor tissue may clinically predict efficacy of capecitabine. "
07/01/2010 - "Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer."
|4.||Stomach Neoplasms (Stomach Cancer)
05/01/2013 - "In practice, when oral therapy is preferred for a patient with advanced gastric cancer, capecitabine is still the best option because it carries a lower risk of serious gastrointestinal adverse effects."
11/01/2014 - "The present case suggests that capecitabine/CDDP therapy may be an effective treatment for S-1 pretreated patients with advanced or metastatic gastric cancer."
10/01/2012 - "S-1 and capecitabine are orally administered fluoropyridines reported to be effective in the treatment of advanced gastric cancer(AGC). "
01/01/2003 - "Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer. "
03/01/2009 - "Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. "
|5.||Rectal Neoplasms (Rectal Cancer)
02/01/2006 - "Preoperative chemoradiation with capecitabine and RT appeared to be effective in locally advanced resectable, rectal cancer. "
01/01/2014 - "The aim of this study was to evaluate the efficacy of helical tomotherapy plus capecitabine as a preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC). "
09/01/2008 - "The objective of this expanded phase II trial was to confirm the safety results of the preceding phase I study and establish the efficacy of neoadjuvant radiochemotherapy with capecitabine in rectal cancer in a multicenter setting. "
08/01/2007 - "The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC). "
02/01/2006 - "The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer. "
|7.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)